



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/658,947	09/09/2003	Sean C. Semple	INEX.P-003-3	3517
32940	7590	08/08/2006	EXAMINER	
DORSEY & WHITNEY LLP			NAFF, DAVID M	
555 CALIFORNIA STREET, SUITE 1000				
SUITE 1000			ART UNIT	PAPER NUMBER
SAN FRANCISCO, CA 94104				1651

DATE MAILED: 08/08/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	10/658,947	SEMPLE ET AL.	
	<b>Examiner</b> David M. Naff	<b>Art Unit</b> 1651	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) Responsive to communication(s) filed on 5/8/06.
- 2a) This action is **FINAL**.      2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) Claim(s) 85-91 and 93-110 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) Claim(s) \_\_\_\_\_ is/are allowed.
- 6) Claim(s) 85-91 and 93-110 is/are rejected.
- 7) Claim(s) \_\_\_\_\_ is/are objected to.
- 8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All    b) Some \* c) None of:
  1. Certified copies of the priority documents have been received.
  2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

- 1) Notice of References Cited (PTO-892)
- 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)  
Paper No(s)/Mail Date 5/8/06.
- 4) Interview Summary (PTO-413)  
Paper No(s)/Mail Date. \_\_\_\_\_.
- 5) Notice of Informal Patent Application (PTO-152)
- 6) Other: \_\_\_\_\_.

**DETAILED ACTION**

An amendment of 5/8/06 amended claims 85-91, 93-101, 105, 107 and 108, added new claims 109 and 110, and canceled claim 92.

Claims examined on the merits are 85-91 and 93-110, which are all 5 claims in the application.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

***Claim Rejections - 35 USC § 112***

Claims 103 and 104 are rejected under 35 U.S.C. 112, first 10 paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Support is not found in the specification for the nucleic acid-lipid particle not being substantially degraded at a temperature and time as required by claims 103 and 104. Example 10 disclosing that free phosphorothioate oligodeoxynucleotide shows significant breakdown in serum within 30 minutes is inadequate support. A time of 20 20 minutes is not found in the specification.

***Response to Arguments***

It is granted as urged by applicants that the claimed subject matter need not be described in the specification literally. However, when not described literally, the specification must provide clear 25 support for the claimed subject matter. Example 10 disclosing that

Art Unit: 1651

free phosphorothioate oligodeoxynucleotide shows significant breakdown in serum within 30 minutes, and the encapsulated nucleic acid not degrading even after 24 hours is inadequate support for selecting 30 minutes as a time less than 24 hours which degradation of the 5 encapsulated nucleic acid does not occur. Selecting 30 minutes for degradation not occurring permits degradation after 30 minutes. This changes the original description in the specification. A time of 20 minutes is not found in the specification as a time for degradation not occurring. For the same type of reasons set forth above in regard 10 to 30 minutes, there is no basis for selecting 20 minutes as a time degradation does not occur, and after which degradation can occur.

***Double Patenting***

Claims 85-91, 93, 97-106 and 108-110 are rejected under the judicially created doctrine of obviousness-type double patenting as 15 being unpatentable over claims 1-21 of U.S. Patent No. 6,858,225 B2 in view of Collins and Cullis et al and Wheeler et al (WO) for reasons set forth in the previous office action of 11/7/05.

***Double Patenting***

Claims 94-96 and 107 are rejected under the judicially created 20 doctrine of obviousness-type double patenting as being unpatentable over claims 1-21 of U.S. Patent No. 6,858,225 B2 in view of the references as applied to claims 85-91, 93, 97-106 and 108-110 above, and further in view of Wheeler et al ('410) and Unger ('276).

It would have been obvious to use DODMA as the amino-lipid of the 25 patent claims as suggested by Wheeler et al ('410) using DODMA (col

51, line 64) as a component of a nucleic acid-lipid particle similar to that of the patent claims. When providing a neutral lipid in the nucleic acid-lipid particle of the patent claims as set forth above, it would have been obvious to use DSPC as the neutral lipid as 5 suggested by Unger disclosing using DSPC in preparing a lipid vesicle.

***Response to Arguments***

Applicants indicate that a terminal disclaimer will be filed when the claims are otherwise allowable.

***Double Patenting***

10 Claims 85-91, 93, 94, 97-106 and 108-110 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-72 of U.S. Patent No. 6,287,591 B1 in view of Collins and Cullis et al for reasons set forth in the previous office action.

15 ***Double Patenting***

Claims 95, 96 and 107 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-72 of U.S. Patent No. 6,287,591 B1 in view of the references as applied to claims 85-91, 93, 94, 97-106 and 108-110 20 above, and in further view of Wheeler et al ('410) for reasons in the previous office action.

***Response to Arguments***

Contrary to applicants' argument, Wheeler et al does not require DODMA-AN. See claim 4, line 6, where DODMA is the cationic lipid.

Applicants indicate that a terminal will be filed when the claims are otherwise allowable.

**Conclusion**

The claims are free of the prior art.

5 **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date 10 of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, 15 however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.


Any inquiry concerning this communication or earlier communications from the examiner should be directed to David M. Naff whose telephone number is 571-272-0920. The examiner can normally be 20 reached on Monday-Friday 9:30-6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mike Wityshyn can be reached on 571-272-0926. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1651

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for 5 unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

10



David M. Naff  
Primary Examiner  
Art Unit 1651

DMN  
8/5/09